Core Insights - Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has achieved a new three-year high following strong earnings and FDA approval for its treatment for familial chylomicronemia syndrome (FCS) [1][3]. Financial Performance - The company reported a significant reduction in its attributable net loss, narrowing it by 99.7% to $1.63 million from $599.49 million the previous year [3]. - Revenues surged by 23,585% to $829.4 million, up from $3.5 million year-on-year [3]. FDA Approval and Product Launch - Arrowhead Pharmaceuticals received FDA approval for its drug redemplo, which is the first and only approved siRNA medicine aimed at reducing triglycerides in adults with FCS [4]. - The company plans to start selling redemplo before the end of the year [4]. Market Context - The FCS disease is rare, affecting approximately 6,500 individuals in the US, characterized by triglyceride levels that can be 10 to 100 times higher than normal, increasing the risk of severe pancreatitis [5].